Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma.
Bi K, He MX, Bakouny Z, Kanodia A, Napolitano S, Wu J, Grimaldi G, Braun DA, Cuoco MS, Mayorga A, DelloStritto L, Bouchard G, Steinharter J, Tewari AK, Vokes NI, Shannon E, Sun M, Park J, Chang SL, McGregor BA, Haq R, Denize T, Signoretti S, Guerriero JL, Vigneau S, Rozenblatt-Rosen O, Rotem A, Regev A, Choueiri TK, Van Allen EM. Bi K, et al. Among authors: mcgregor ba. Cancer Cell. 2021 May 10;39(5):649-661.e5. doi: 10.1016/j.ccell.2021.02.015. Epub 2021 Mar 11. Cancer Cell. 2021. PMID: 33711272 Free PMC article.
Immunotherapy in the Elderly.
Lalani AA, Bossé D, McGregor BA, Choueiri TK. Lalani AA, et al. Among authors: mcgregor ba. Eur Urol Focus. 2017 Oct;3(4-5):403-412. doi: 10.1016/j.euf.2017.11.008. Epub 2017 Nov 26. Eur Urol Focus. 2017. PMID: 29183736 Review.
JAVELIN: avelumab another spear to fight urothelial carcinoma.
Lalani AA, McGregor BA, Sonpavde GP, Choueiri TK. Lalani AA, et al. Among authors: mcgregor ba. Lancet Oncol. 2018 Jan;19(1):5-7. doi: 10.1016/S1470-2045(17)30901-4. Epub 2017 Dec 5. Lancet Oncol. 2018. PMID: 29217289 No abstract available.
Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma.
Lalani AA, Xie W, Martini DJ, Steinharter JA, Norton CK, Krajewski KM, Duquette A, Bossé D, Bellmunt J, Van Allen EM, McGregor BA, Creighton CJ, Harshman LC, Choueiri TK. Lalani AA, et al. Among authors: mcgregor ba. J Immunother Cancer. 2018 Jan 22;6(1):5. doi: 10.1186/s40425-018-0315-0. J Immunother Cancer. 2018. PMID: 29353553 Free PMC article.
Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events.
Martini DJ, Hamieh L, McKay RR, Harshman LC, Brandao R, Norton CK, Steinharter JA, Krajewski KM, Gao X, Schutz FA, McGregor B, Bossé D, Lalani AA, De Velasco G, Michaelson MD, McDermott DF, Choueiri TK. Martini DJ, et al. Cancer Immunol Res. 2018 Apr;6(4):402-408. doi: 10.1158/2326-6066.CIR-17-0220. Epub 2018 Feb 1. Cancer Immunol Res. 2018. PMID: 29437040
148 results